Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Policy / Regulatory

CDE Reference Standards 101st Batch Seeks Public Feedback

Fineline Cube Dec 23, 2025
Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Fineline Cube Dec 23, 2025
Company Drug

3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery

Fineline Cube Dec 23, 2025
Company Deals

ArieMedi Secures Series A+ Financing to Expand Precision Navigation Solutions

Fineline Cube Oct 26, 2022

ArieMedi Medical Science, a leading precision navigation solutions provider based in Beijing, has announced the...

Company Deals

ClinBrain Raises RMB 200 Million in Series C Financing to Boost Medical Big Data

Fineline Cube Oct 26, 2022

Shanghai-based ClinBrain, a leading clinical data repository (CDR) and medical big data services provider, has...

Company Drug

Covis Pharma’s COPD Therapies Show Positive Results in Phase III AVANT Trial

Fineline Cube Oct 26, 2022

Luxembourg-based Covis Pharma Group has released positive topline data from its Phase III AVANT trial,...

Company

Huadong Medicine Reports 10.4% Revenue Growth in Q3 2022

Fineline Cube Oct 26, 2022

Huadong Medicine Co., Ltd (SHE: 000963) has published its Q3 2022 financial report, revealing robust...

Company Drug

CSPC Receives CDE Approval for Generic Version of Pfizer’s Xeljanz

Fineline Cube Oct 26, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received market...

Company Deals

Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion

Fineline Cube Oct 25, 2022

China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367) has announced plans to...

Company Deals

BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda

Fineline Cube Oct 25, 2022

China-based BIMI International Medical Inc. (OTCMKTS: BIMI), a wholesaler of drugs and healthcare products, has...

Company Deals

Shandong Branden Medical Devices Files for IPO on STAR Board to Raise RMB 760M

Fineline Cube Oct 25, 2022

China-based Shandong Branden Medical Devices Co., Ltd has filed for an initial public offering (IPO)...

Company Deals

Gan & Lee Pharmaceuticals Plans RMB 814M Private Placement for Working Capital

Fineline Cube Oct 25, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced plans to raise up to RMB...

Company Deals

Rongsheng Bio Set for IPO on STAR Board to Boost Vaccine R&D

Fineline Cube Oct 25, 2022

Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of...

Company Drug

Daiichi Sankyo Initiates Global Phase II Study of DS7300 for Small-Cell Lung Cancer

Fineline Cube Oct 25, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) has announced the first patient dosing in a global...

Company Drug

Abbisko’s ABSK021 Gets CDE Approval for Phase III Study in Giant Cell Tumor of Tendon Sheath

Fineline Cube Oct 25, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

Livzon Launches National Rollout of COVID-19 Vaccine V-01 in China

Fineline Cube Oct 25, 2022

China-based Livzon Pharmaceutical Group (HKG: 1513) has announced the national promotion of its recombinant novel...

Company Deals

Venmedtech Raises Series B+ Funding for Iliac Vein Stent and Product R&D

Fineline Cube Oct 25, 2022

Venmedtech, a Suzhou-based one-stop intravenous therapy product platform, has reportedly raised “tens of millions” of...

Company Deals

Celgenyx Completes RMB 100M Series A Financing for Next-Gen Cell Therapy Development

Fineline Cube Oct 25, 2022

China-based Hangzhou Celgenyx Gene Technology Co., Ltd has announced the completion of a Series A...

Company Deals

Easy-Flow Medical Secures Angel Funding for Peripheral Device Development

Fineline Cube Oct 25, 2022

China-based peripheral interventional device manufacturer Shanghai Easy-Flow Medical Tech Co., Ltd has reportedly raised “tens...

Company Drug

Hengrui Medicine Gains Approval for Phase Ib/II Study of SHR-A1811 and SHR-1701 in HER2-Positive Gastric Cancer

Fineline Cube Oct 24, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval to initiate a...

Company Deals

Zhejiang Pushkang Biotech Raises RMB 100M in Series C+ Financing

Fineline Cube Oct 24, 2022

China-based Zhejiang Pushkang Biotechnology Co., Ltd, a leading centrifugal microfluidic platform company, has reportedly raised...

Company Deals R&D

Sinovac Partners with Colombia University to Boost Vaccine R&D

Fineline Cube Oct 24, 2022

China’s Sinovac (NASDAQ: SVA) has announced a partnership with Universidad de Antioquia of Colombia (UdeA)...

Company Deals

SeeNeuro Medical Raises RMB 100M in Series B Funding for Neural Regulation Devices

Fineline Cube Oct 24, 2022

Hangzhou-based SeeNeuro Medical, a developer of implantable neural regulation devices, has reportedly raised RMB 100...

Posts pagination

1 … 546 547 548 … 601

Recent updates

  • Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections
  • Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal
  • 3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery
  • Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment
  • Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Company Drug

3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery

Company Drug

Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.